Zenas BioPharma Financial Statements
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma revenue and earnings
In fiscal 2025, Zenas BioPharma generated $10.0 million in revenue, up 100.0% from fiscal 2024. Zenas BioPharma reported a net loss of $377.7 million, compared with a loss of $157.0 million a year earlier. Operating margin was -3830.6%.
Diluted earnings per share came in at -$8.44. Over the last 2 fiscal years, ZBIO's revenue has grown at a -55.3% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 10.00M | 5.00M | 50.00M |
| Revenue growth (YoY) | +100.00% | -90.00% | — |
| Operating Expenses | 393.06M | 168.89M | 87.15M |
| Research & Development | 168.06M | 139.14M | 60.03M |
| Operating Income | -383.06M | -163.89M | -37.15M |
| Interest Expense | 7.33M | — | — |
| Other Income (Expense) | 5.24M | 7.33M | 324.00K |
| Pretax Income | -377.82M | -156.56M | -36.82M |
| Income Tax | -79.00K | 429.00K | 301.00K |
| Net Income | -377.74M | -156.99M | -37.12M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -8.44 | -11.89 | -24.25 |
| EPS (Diluted) | -8.44 | -11.89 | -24.25 |
| Shares Outstanding (Basic) | 44.73M | 13.20M | 1.53M |
| Shares Outstanding (Diluted) | 44.73M | 13.20M | 1.53M |
| EBITDA | -383.00M | -163.75M | -37.03M |
| Operating Margin | -3830.57% | -3277.76% | -74.29% |
| Net Margin | -3777.37% | -3139.76% | -74.25% |
This table shows 3 annual periods of Zenas BioPharma's income statement, from FY 2025 back to FY 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ZBIO's reporting calendar. What is a income statement?